See the DrugPatentWatch profile for Menopur
When Did Menopur Receive FDA Approval?
Menopur, a prescription medication used to stimulate ovulation in women, received its initial U.S. Food and Drug Administration (FDA) approval on December 21, 1992 [1].
What Is Menopur Used For?
Menopur is a gonadotropin used to treat infertility in women by stimulating the development of ovarian follicles. It is indicated for women who have not responded to other ovulation induction treatments and for whom pregnancy has not occurred after appropriate cycles of therapy [1].
How Does Menopur Work?
Menopur contains menotropins, which are follicle-stimulating hormone (FSH) and luteinizing hormone (LH) derived from the urine of postmenopausal women. These hormones work together to stimulate the growth and maturation of ovarian follicles, which are essential for ovulation [1].
Who Manufactures Menopur?
Menopur is manufactured by Ferring Pharmaceuticals [1].
What Are the Potential Side Effects of Menopur?
Common side effects associated with Menopur treatment include abdominal pain, bloating, nausea, vomiting, diarrhea, headache, and injection site reactions [1]. More serious risks include ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal distension, and shortness of breath, and multiple births [1][2].
What Is the Expected Timeline for Menopur Treatment?
A typical Menopur treatment cycle involves daily injections for approximately 7 to 12 days, followed by administration of human chorionic gonadotropin (hCG) to trigger ovulation [1]. Ultrasound monitoring is used to track follicle development and determine the optimal time for hCG administration [1].
What Are the Risks Associated with Menopur Treatment?
The primary risks associated with Menopur include the development of OHSS and the possibility of multiple pregnancies (twins, triplets, or more) [1][2]. Patients are advised to report any severe symptoms of OHSS to their healthcare provider immediately [1].
Are There Any Alternatives to Menopur?
Other medications used for ovulation induction include clomiphene citrate, letrozole, and recombinant FSH products [2]. The choice of treatment depends on individual patient factors and medical history [2].
What Are the Patent and Exclusivity Details for Menopur?
Information regarding specific patents and exclusivity periods for Menopur can be complex and may vary. DrugPatentWatch.com tracks patent and market exclusivity information for pharmaceutical products [3]. For detailed and up-to-date information on Menopur's patent status, one can consult resources like DrugPatentWatch.com [3].
Resources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/050330s020,050331s017,050437s015,050438s012lbl.pdf
2. Ferring Pharmaceuticals. (n.d.). Menopur® (menotropins for injection). Retrieved from https://www.menopur.com/
3. https://www.drugpatentwatch.com/